KKR exits Nordic Bioscience, selling 10% stake to founder
What's the deal? KKR has agreed to sell its 10% minority stake in Danish biomarker company Nordic Bioscience to founder and majority shareholder Claus ChristiansenDealroom has a profile for this one. Try Dealroom →. The Copenhagen firm announced the transaction on September 3, 2026, ending a partnership that began in 2021.
What each side does: Nordic Bioscience develops biomarkers for R&D services, clinical diagnostics, and drug development, built around its expertise in the extracellular matrix. KKR, the global investment firm, invested through its Health Care Strategic Growth strategy.
By the numbers: Nordic Bioscience doubled revenue and grew more profitable during KKR's five-year involvement, according to Christiansen. The company holds a patented portfolio of more than 150 biomarkers across disease areas including liver, cancer, and obesity.
What changes? Chair Håkan Björklund will step down from the board, and Christiansen will take over as chair. Kugan Sathiyanandarajah, a KKR partner, remains on the board until the next ordinary general meeting.
Why now? KKR frames the exit as the natural end of a strategic partnership. "We are pleased with the value created during our strategic partnership and believe Nordic Bioscience is well positioned for its next phase of growth," Sathiyanandarajah said.
The signal: The buyback returns full ownership to the founder, a route private equity investors increasingly take when a fund's holding period ends and the founder retains a majority stake. For Nordic Bioscience, it means independence to pursue its next growth phase across its three business areas.
Image credit: History at NIH
